Journal article
Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression
D Cheasley, ML Fernandez, M Köbel, H Kim, A Dawson, J Hoenisch, M Bittner, DS Chiu, A Talhouk, CB Gilks, MW Jayawardana, KI Pishas, AM Mes-Masson, D Provencher, A Nigam, NF Hacker, KL Gorringe, IG Campbell, MS Carey
Npj Precision Oncology | Published : 2022
Abstract
Hormone receptor expression is a characteristic of low-grade serous ovarian carcinoma (LGSOC). Studies investigating estrogen receptor (ER) and progesterone receptor (PR) expression levels suggest its prognostic and predictive significance, although their associations with key molecular aberrations are not well understood. As such, we sought to describe the specific genomic profiles associated with different ER/PR expression patterns and survival outcomes in a cohort of patients with advanced disease. The study comprised fifty-five advanced-staged (III/IV) LGSOCs from the Canadian Ovarian Experimental Unified Resource (COEUR) for which targeted mutation sequencing, copy-number aberration, cl..
View full abstractGrants
Awarded by BC Cancer Agency
Funding Acknowledgements
This project was supported by funding from the Australian Gynaecological Cancer Foundation, the Way-in Network, the National Health and Medical Research Council, Cancer Australia, the Terry Fox Research Institute, the British Columbia Cancer Foundation, Ovarian Cancer Canada/OvCAN Initiative, Cure our Ovarian Cancer, the Canadian Institutes of Health Research Planning and Dissemination, the Women's Health Research Institute and the Vancouver General/UBC Hospital Foundation. The authors would like to acknowledge the Bioinformatics and Molecular Genomics Core Facilities of the Peter MacCallum Cancer Centre, which are supported by the Peter MacCallum Foundation and the Australian Cancer Research Foundation. This study also used resources provided by the Canadian Ovarian Cancer Research Consortium's COEUR biobank funded by the Terry Fox Research Institute and supervised by the CHUM. The Consortium acknowledges contributions to its COEUR biobank from institutions across Canada (for a full list see http://www.tfri.ca/en/research/translational-research/coeur/coeur_biobanks.aspx).We would like to thank all of the women who participated in these research programs. This work was also supported by the British Columbia Cancer Foundation. The authors want to extend a special thanks to the MacKenzie, Lawler, MacRae, Ho, Ludemann, and Luther families, the Janet D. Cottrelle Foundation, and to all patients, families, and donors who supported this research. We would also like to thank the Society of Gynecologic Oncology of Canada for their support in advancing research and knowledge translation in LGSOC.